Carl H. June
for the development of chimeric antigen receptor T cell immunotherapy whereby the patient's T cells are modified to target and kill cancer cells.
La reconnaissance d'un travail ayant un impact durable
for the development of chimeric antigen receptor T cell immunotherapy whereby the patient's T cells are modified to target and kill cancer cells.